Your trusted CRO partner for preclinical studies of acute and chronic kidney disease

Our mission is to accelerate the development of novel therapies to treat kidney disease by combining scientific excellence with robust and reproducible preclinical models.
Get in touch Learn more

Our services

We provide high-quality, cost-effective in vivo and ex vivo models to study acute and chronic kidney disease and diabetic nephropathy. We are located at Karolinska Institutet 's campus in Stockholm with access to state-of-the-art technologies, including in vivo imaging, single-cell and bulk RNA sequencing, spatial transcriptomics, proteomics, super-resolution microscopy and AI-assisted histology analysis.

Our models of acute kidney injury (AKI) include ischemia-reperfusion injury (IRI), anti-GMB nephritis, and folic acid- and sepsis-induced acute kidney injury.

Our models of chronic kidney disease (CKD) include adenine-induced nephropathy, 5/6 nephrectomy, unilateral ureter obstruction (UUO) and the Col4a3 knockout mouse model of Alport syndrome.

Our models of diabetic nephropathy (DN) includes Streptozotocin (STZ)-induced diabetes type 1 and the Renin-AAV, unilateral nephrectomy, db/db mouse model of accelerated type 2 diabetes. 

Together with the Preclinical Imaging Facilityat KI we offer state-of-the-art preclinical imaging technologies including IVIS, μCT, ultrasound, PET/MRI and MPI. 

We offer cutting-edge bulk and single cell RNA sequencing, and spatial transcriptomic methods via KI core facilities and SciLifeLab.

Through collaborations with Magnephy and Aiosyn we offer super-resolution microscopy and AI-assisted histology analysis. 
Read more about our services

About us

Alvolab (from the Portuguese word 'Alvo', meaning 'Target') is a contract research organization specialized in preclinical studies of acute and chronic kidney disease. Founded in 2023 as a spin-off from Karolinska Institutet, our team brings over 30 years of experience in translational kidney research from leading academic institutions including Harvard Medical School, Karolinska Institutet, and Uppsala University, as well as from the pharmaceutical industry.
Our mission is to accelerate the development of novel therapies to treat kidney disease by combining scientific excellence with robust and reproducible preclinical models. To that end, we provide high-quality, cost-effective in vivo and ex vivo models to study acute and chronic kidney disease and diabetic nephropathy. 
Contact us to learn more about our services and what we can do for your organization or company.
Meet the Alvolab team
Client 1
Use this testimonial to highlight your professional experience and customer satisfaction
Client 2
Use this testimonial to highlight your professional experience and customer satisfaction
Name E-mail Message Submit

Contact us

Reach out to learn more about our services and what we can offer your organization or company

Visionsgatan 56, 171 64 Solna, Sweden

+46 733 665 449

hello@alvolab.com